Navigation Links
Coley Pharmaceutical Group to Report Third Quarter Results on November 1, 2007
Date:10/25/2007

WELLESLEY, Mass., Oct. 25 /PRNewswire-FirstCall/ -- Coley Pharmaceutical Group, Inc. (Nasdaq: COLY), today announced that the company will host an investor conference call at 4:30 p.m. Eastern Time on November 1, 2007 to discuss second quarter 2007 financial results.

To access the live audio broadcast or the subsequent archived recording of the call, please visit the Investor Center section of the Coley website at http://www.coleypharma.com. Please log onto Coley's website several minutes prior to the start of the call to ensure adequate time for any software download that may be required. A replay of this webcast will be available through November 15, 2007.

Investors may participate in the conference call by dialing either + 1- 888-713-4217 in the U.S. or + 1-617-213-4869 outside the U.S. and typing in the passcode 20929767. A replay of this call will be available at + 1-888- 286-8010 (U.S.) or +1- 617-801-6888 (international) using the passcode 82770375 until November 15, 2007.

The webcast is also being distributed through the Thomson StreetEvents Network to both institutional and individual investors. Individual investors can listen to the call at http://www.fulldisclosure.com and institutional investors can access the call via http://www.streetevents.com.

About Coley Pharmaceutical Group

Coley Pharmaceutical Group, Inc. is an international biopharmaceutical company, headquartered in Wellesley, Massachusetts, USA, that discovers and develops TLR Therapeutics(TM), a new class of investigational drug candidates that direct the human immune system to fight cancers, allergy and asthma disorders and to enhance the effectiveness of vaccines. Coley has established a pipeline of TLR Therapeutic product candidates currently advancing through clinical development with partners and has additional product candidates in preclinical development. Coley has product development, research and license agreements with Pfizer, sanofi-aventis, GlaxoSmithKline, Merck, Novartis Vaccines and the United States government. For further information on Coley Pharmaceutical Group please visit http://www.coleypharma.com.

Safe Harbor Statement

Certain statements in this news release concerning Coley's business are considered "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Any or all of the forward-looking statements in this press release may turn out to be wrong. They can be affected by inaccurate assumptions Coley might make or by known or unknown risks and uncertainties, including, but not limited to: the early stage of product development; uncertainties as to the future success of ongoing and planned clinical trials; the risk that results from early stage clinical trials may not be indicative of results in later stage trials; the unproven safety and efficacy of products under development; intellectual property rights and litigation; competitive products; and other risks identified in Coley's filings with the Securities and Exchange Commission including, but not limited to, Coley's Annual Report on Form 10-K for the fiscal year ended December 31, 2006. Consequently, no forward-looking statement can be guaranteed, and actual results may vary materially. Coley undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise, except as required by applicable law.


'/>"/>
SOURCE Coley Pharmaceutical Group, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. South Africa Wins landmark case against pharmaceutical giants
2. Pharmaceutical giant offers AIDS related antifungal drug free to 50 countries
3. Pharmaceutical giant offers AIDS related antifungal drug free to 50 countries
4. Setting up a new pharmaceutical industry in India
5. Medicis Pharmaceutical company enters pediatric market
6. Supply of Radiopharmaceuticals Hampered by Attacks
7. Pharmaceutical companies are targeting patients
8. FDA approves Watson Pharmaceuticals Oxytrol patch
9. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
10. Indian Pharmaceutical Industries Stops Manufacturing And Sale Of Valdecoxib
11. Pharmaceutical industries grant for R&D to be monitored
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... March 29, 2017 , ... AngioGenesis Labs sold 300 bottles ... AngioGenesis Labs, makers of HeartBoost, BrainBest and BeautyBest, achieved these results while doing ... an over the counter heart healthy drink, can reduce Arterial Plaque, Lower Blood ...
(Date:3/29/2017)... ... March 29, 2017 , ... Based on research ... challenges employers face in trying to balance both short-term and long-term benefits demands. ... Adding to the growing complexity, companies are finding that the short-term strategies used ...
(Date:3/29/2017)... ... ... Dr. Angela Cotey, a noted general dentist in Mt. Horeb, is now ... without a referral. Dr. Cotey knows that interceptive orthodontics in Mt. Horeb, ... receive early treatment, they may achieve straight teeth with less treatment in their teenage ...
(Date:3/29/2017)... ... March 29, 2017 , ... How ... other outpatient facilities, and who are the most active developers? , In ... and Healthcare Real Estate Insights (HREI) found that outpatient medical real estate development ...
(Date:3/29/2017)... ... March 29, 2017 , ... Curio Wellness , a premium medical cannabis ... the company’s executive management team with prominent executives from both inside and outside the ... Operating Officer, Ted Dumbauld , who has more than twenty years of business ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... , March 29, 2017 ... report, which provides an exhaustive study of the U.S. ... nearly 242 companies are functional in this market ... With the leading companies, such as GlaxoSmithKline Plc., ... focusing aggressively on various marketing strategies to increase ...
(Date:3/29/2017)... 29, 2017 Research and Markets has announced ... report to their offering. ... The global lifestyle drugs market to grow at a ... report, Global Lifestyle Drugs Market 2017-2021, has been prepared based on ... covers the market landscape and its growth prospects over the coming ...
(Date:3/29/2017)... -- Varian Medical Systems (NYSE: VAR ) announced ... of fiscal year 2017 following the close of regular trading ... followed by a teleconference available to all interested parties at ... the conference call webcast will be available on the company ... and replay: ...
Breaking Medicine Technology: